A U.S. House committee has initiated investigations into several pharmaceutical companies, including Merck and AbbVie, over their drug trials conducted in China. Concerns have arisen regarding the involvement of military-linked hospitals in these trials, prompting lawmakers to demand explanations from the companies. Eli Lilly has also faced scrutiny related to similar issues. The investigations come amidst broader national security concerns regarding the ties between U.S. drugmakers and Chinese military interests. Additional probes have been opened into Bristol Myers Squibb and Pfizer about their trial sites in China, as bipartisan efforts intensify to ensure compliance with ethical standards and safeguard national interests.